Mark Cuban on Cost Plus Drugs, Hiring and Healthcare Pricing

Mark Cuban introduces Cost Plus Drugs as a pharmacy business intended to sell generic medicines with transparent pricing. In this 2022 interview he describes a 15% markup, a $3 handling fee and $5 shipping. Those are his historical terms, not a current price quote; actual prices, fees, eligibility and availability require checking with the provider.

Cuban claims the resulting price is often below what patients otherwise pay, sometimes including an insurance copay. He does not provide evidence supporting his numerical estimate, and the comparison depends on the specific medicine, pharmacy and insurance coverage. His statements come from the business’s owner and financier.

He says he financed the business himself rather than bringing in investors and wanted a low-cost offering without extra services. He portrays pharmacy benefit managers and insurance administration as adding complexity and says the service at that time did not accept insurance. These are his description of the early model and his interpretation of the industry.

Asked how manufacturers and competitors might respond, Cuban predicts some may match prices if the business becomes large enough while others may ignore it. The outcome depends on market behavior and is not established in the interview. He says self-funding gives him patience to pursue the effort.

Cuban says he began studying healthcare costs years earlier and later corresponded with physician Alex Oshmyansky, who became his partner. He recounts considering ways to obtain a high-priced generic drug and learning that distribution and legal rules complicated his initial idea. This is his account, not legal advice or an independent analysis of drug law.

The business idea, he says, was to buy and sell medicines at lower prices while making enough to reinvest. He dates the start to around 2017 or 2018. He says regulation, infrastructure and persuading suppliers that the project would continue were difficult parts of getting started.

Cuban declines to provide a precise investment total but says he had committed tens of millions of dollars and expected that to grow. He credits his partners and staff with handling operational and pharmaceutical details while he focuses more on communication and connections. The amount and roles are his historical account.

He admits hiring is not his strongest skill: as a salesperson he can become convinced by a candidate and rush the process. He recommends taking time to assess a hire and delegating to colleagues who are better at evaluating people. He also values promoting capable people internally.

Cuban describes his approach to trust as “trust but verify.” After someone repeatedly delivers, he is willing to delegate more. When performance falls short, he prefers a direct discussion of the problem, expectations and support required, although he acknowledges that the circumstances of the labor market can make the conversation difficult.

He separates what he calls stress creators from stress removers and says he tries to retain people who reduce recurring problems. His percentages about employee awareness are conversational estimates rather than measured workforce data. He focuses goals on what a business can do well and how it can serve customers efficiently.

For Cost Plus, he says the goal is not simply sales but serving and retaining customers who trust its pricing. He expects adding medicines and lowering prices when possible to encourage word of mouth. These are the company’s stated goals, not a guarantee that its prices will always fall or be lowest.

Cuban argues that understanding why customers choose a product can make marketing easier than immediately buying advertising. He expects patients with the same needs to share information with one another. His strategy depends on customer behavior and should not be taken as evidence that a particular medicine is appropriate for anyone.

He says the service was scaling rapidly and credits fulfillment partner Truepill with capacity and agility. His account and reported signup pace describe the early 2022 period, not current users or prescription volume. He identifies manufacturer supply capacity as a possible challenge at larger scale.

Rather than expanding immediately into insurance, Cuban says the company must first execute its existing pharmacy business. He offers a critical view of incentives among insurers and hospitals, using illustrative premium and pricing examples. These are his interpretation and simplifications, not an accounting of any particular insurer or patient’s coverage.

Cuban cites an estimate for US healthcare administration costs and discusses trade-offs he sees between single-payer and hybrid systems. The interview does not establish his percentage or legal details, so they should not be treated as verified statistics or current policy guidance. He expresses a preference for a hybrid approach.

He says starting the business required answering familiar questions about the customer, the service, delivery and the people who will do the work. He praises his partners and says he focuses on nearer-term execution rather than a detailed five-year forecast for Cost Plus.

Cuban contrasts that with past technology ventures where he tried to imagine how infrastructure might evolve. He also speculates about decentralized approaches to insurance claims. That is a technology prediction, not evidence that such a system is established, lawful for a particular use or better for patients.

In the rapid-fire round, he criticizes the healthcare system while expressing respect for doctors and nurses. His allegations about hospital costs and incentives are his opinions in the interview and are not independently established here.

He says a discussion with constitutional lawyers caused him to reconsider his position on legal protection for algorithmically amplified speech. He attributes his changed view to their argument. The exchange is a personal account from 2022, not a legal conclusion.

Cuban names climate change as a major worry for his children’s future and frames his concern in terms of risk. He wants his children to value learning and effort. These are personal priorities, and the interview does not quantify climate risk or evaluate his later offset purchases.

He describes trying to be available and caring as a parent and jokes that his wife is more often the person to whom their children confide. Asked about marriage, he credits her and notes that financial security reduces stress for his family. His experience is personal and reflects his resources.

He says he hopes to improve healthcare beginning with generic drugs and names a private plane as a purchase that saves him time. He acknowledges the tension with his climate concerns and mentions buying offsets; the interview does not verify their effectiveness. He closes by inviting feedback on Cost Plus, a business in which he has a financial interest.